SCHEMBL23538286

SCHEMBL23538286

COC(OCC[Si](C)(C)C)c1ccc2c(C=O)c[nH]c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 1/20 0.48
MAPT P10636 1/20 0.48
CYP2A6 P11509 2/20 0.42
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
PLG P00747 1/20 0.38
PLAU P00749 1/20 0.38
IMPDH2 P12268 1/20 0.37
CCNT1 O60563 1/20 0.35
CDK9 P50750 1/20 0.35
HASPIN Q8TF76 1/20 0.35
PIK3CD O00329 1/20 0.34
ABL1 P00519 1/20 0.34
EGFR P00533 1/20 0.34
HCK P08631 1/20 0.34
SRC P12931 1/20 0.34
KDR P35968 1/20 0.34
PIK3CA P42336 1/20 0.34
MTOR P42345 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23538113 0.81 ALDH1A1 (0.43) ALDH1A1KDM4EMAPTCYP2A6CYP1A2
SCHEMBL27601642 0.72 ALDH1A1 (0.53) ALDH1A1KDM4EMAPTCYP2A6CYP1A2
SCHEMBL3433878 0.72 CYP2A6 (0.58) ALDH1A1KDM4EMAPTCYP2A6CYP1A2
SCHEMBL23538121 0.70 MAPT (0.38) MAPT
SCHEMBL23538279 0.69
SCHEMBL27652472 0.67 ALDH1A1 (0.49) ALDH1A1KDM4EMAPTCYP2A6CYP1A2
SCHEMBL671759 0.66 ALDH1A1 (1.00) ALDH1A1KDM4EMAPTCYP2A6CYP1A2
SCHEMBL29954469 0.66 ALDH1A1 (1.00) ALDH1A1KDM4EMAPTCYP2A6CYP1A2
SCHEMBL15323821 0.66 ALDH1A1 (0.45) ALDH1A1KDM4EMAPTCYP2A6CYP1A2
SCHEMBL20590766 0.64 CYP2A6 (0.55) ALDH1A1KDM4EMAPTCYP2A6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021127302-A1 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS Ikena Oncology, Inc. (US) 2021-06-24 WO disclosed